Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY)

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is highlighted as a strong investment opportunity in the pharmaceutical sector, with Jefferies maintaining a Buy rating and a price target of $68 [1]. Group 1: Analyst Ratings - Scotiabank raised its price target for Bristol-Myers Squibb from $45 to $53 while keeping a Sector Perform rating, citing expectations for pivotal data readouts in 2026 that present an upside risk/reward [2]. - Leerink also maintained an Outperform rating as the company expands its ADEPT-2 enrollment [2]. Group 2: FDA Approval and Product Details - The FDA approved Breyanzi for treating adult patients with relapsed or refractory marginal zone lymphoma who have undergone at least two prior systemic therapies, marking it as the only FDA-approved CAR T cell therapy for five cancer types [3][4]. - Breyanzi demonstrated a durable response in 95.5% of patients in the MZL cohort of the TRANSCEND FL study, alongside a consistent safety profile [4]. Group 3: Company Overview - Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering advanced medicines for serious diseases across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience [5].